Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation
- PMID: 559691
- PMCID: PMC372340
- DOI: 10.1172/JCI108766
Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation
Abstract
To evaluate the contribution of genetic influences on the individual variation in plateau serum salicylate levels, salicylate metabolism was studied in seven pairs of identical and six pairs of fraternal twins.Under the conditions of this study, after a single i.v. dose (40 mg/kg) of sodium salicylate, the serum salicylate concentration versus time curve approximated a straight line on linear coordinates (appeared approximately zero order). The slopes of the decay curves ranged between 0.64 and 1.02. The intrapair variation for identical twin pairs was significantly less than for fraternal twin pairs (P = 0.044). Likewise pleateau serum salicylic acid concentrations (milligrams/deciliter) and total salicylic acid excretion rate after multiple doses demonstrated significantly less intrapair variation for identical twins than for fraternal twins (P = 0.043 and 0.006). Plateau salicylurate excretion (milligram/kilogram per hour) differences after multiple dosing had a P = 0.067. Michaelis-Menton constant for salicylurate formation and hours to 50% excretion after the i.v. dose were not different when comparing identical and nonidentical twins. Salicylurate formation rates were increased after 3 days of oral therapy, and this induction phenomenon may account for much of the apparent discrepancy between genetic influences on salicylurate formation rates observed after single and multiple dose salicylate administration. This study suggests that the plateau concentration of serum salicylate varies among individuals given the same weight-adjusted dose in part because of genetically determined variations in their metabolism of salicylate.
Similar articles
-
Pharmacokinetics, metabolism and disposition of salicylate in protein-deficient rats.Drug Metab Dispos. 1982 Mar-Apr;10(2):147-52. Drug Metab Dispos. 1982. PMID: 6124400
-
Polymorphism of theophylline metabolism in man.J Clin Invest. 1985 May;75(5):1415-25. doi: 10.1172/JCI111843. J Clin Invest. 1985. PMID: 4039734 Free PMC article.
-
Correlation of plateau serum salicylate level with rate of salicylate metabolism.Clin Pharmacol Ther. 1975 Sep;18(3):350-5. doi: 10.1002/cpt1975183350. Clin Pharmacol Ther. 1975. PMID: 1100304 Clinical Trial.
-
Kinetics of salicylate elimination by anephric patients.J Clin Invest. 1974 Nov;54(5):1221-6. doi: 10.1172/JCI107865. J Clin Invest. 1974. PMID: 4424666 Free PMC article.
-
Pharmacokinetics of salicylate in man.Drug Metab Rev. 1979;9(1):3-19. doi: 10.3109/03602537909046431. Drug Metab Rev. 1979. PMID: 36267 Review. No abstract available.
Cited by
-
Salicylate pharmacokinetics in patients with rheumatoid arthritis.Br J Clin Pharmacol. 1989 Oct;28(4):449-61. doi: 10.1111/j.1365-2125.1989.tb03526.x. Br J Clin Pharmacol. 1989. PMID: 2590603 Free PMC article.
-
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.J Pharmacokinet Biopharm. 1991 Oct;19(5):575-95. doi: 10.1007/BF01062964. J Pharmacokinet Biopharm. 1991. PMID: 1783992
-
Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.Eur J Clin Pharmacol. 1987;32(2):153-8. doi: 10.1007/BF00542188. Eur J Clin Pharmacol. 1987. PMID: 3582479
-
Nonlinear pharmacokinetics: clinical Implications.Clin Pharmacokinet. 1991 Jun;20(6):429-46. doi: 10.2165/00003088-199120060-00001. Clin Pharmacokinet. 1991. PMID: 2044328 Review.
-
Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient.Drug Saf. 1990 Sep-Oct;5(5):317-27. doi: 10.2165/00002018-199005050-00002. Drug Saf. 1990. PMID: 2222866 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources